{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:56:03Z","timestamp":1786118163924,"version":"build-2736575974"},"reference-count":26,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Renin-angiotensin-aldosterone system inhibitors (RAASi) are suggested for treating albuminuria in patients with sickle cell disease (SCD). RAASi may exacerbate anemia in the general population and those with diabetes through unclear mechanisms. The impact of RAASi on anemia in chronic hemolytic disorders, such as SCD, is unknown. In a cross-sectional analysis of 658 Walk-PHaSST participants, RAASi use was independently associated with lower hemoglobin concentrations, adjusting for age, sex, SCD genotype, estimated glomerular filtration rate, and erythroid-stimulating agent and hydroxyurea use (\u03b2, \u22120.46 \u00b1 0.21; P = .032). In 2 longitudinal cohorts (University of Illinois Chicago, n = 24; multicenter losartan clinical trial, n = 32), RAASi therapy led to a reduction in hemoglobin concentrations compared with pretreatment values by \u22120.44 \u00b1 0.14 g\/dL (P = .006) and \u22120.53 \u00b1 0.17 g\/dL (P = .005), respectively. SCD mice treated with losartan demonstrated lower hemoglobin concentrations after 6 and 14 weeks (P&amp;lt; .001) and lower absolute reticulocyte counts by 14 weeks (P = .03) vs control mice without changes in circulating erythropoietin, interleukin-12p70 (IL-12p70), IL-3, or insulin-like growth factor 1 levels. Bone marrow cells from losartan-treated SCD mice had lower colony-forming units (P \u2264 .09) with rescue of erythroid colony formation after exogenous erythropoietin supplementation (P = .02). Bone marrow histopathology demonstrated reduced erythroid relative to myeloid ratios in losartan-treated vs untreated SCD mice. Hemoglobin levels should be closely monitored when using RAASi in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033813","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:01:53Z","timestamp":1780336913000},"page":"783-788","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Renin-angiotensin-aldosterone system inhibition exacerbates anemia in sickle cell disease"],"prefix":"10.1182","volume":"148","author":[{"given":"Najmeh","family":"Eskandari","sequence":"first","affiliation":[{"name":"1Comprehensive Sickle Cell Center, Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Pappano","sequence":"additional","affiliation":[{"name":"1Comprehensive Sickle Cell Center, Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Armila","family":"Ruiz","sequence":"additional","affiliation":[{"name":"1Comprehensive Sickle Cell Center, Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3113-9155","authenticated-orcid":false,"given":"Nadim","family":"Mahmud","sequence":"additional","affiliation":[{"name":"1Comprehensive Sickle Cell Center, Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"},{"name":"2Blood and Marrow Transplant Program, University of Illinois Hospital, Health Sciences System, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Ren","sequence":"additional","affiliation":[{"name":"1Comprehensive Sickle Cell Center, Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3185-1786","authenticated-orcid":false,"given":"Zalaya","family":"Ivy","sequence":"additional","affiliation":[{"name":"1Comprehensive Sickle Cell Center, Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-5749","authenticated-orcid":false,"given":"Sujata","family":"Gaitonde","sequence":"additional","affiliation":[{"name":"3Department of Pathology, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4725-7295","authenticated-orcid":false,"given":"Victor R.","family":"Gordeuk","sequence":"additional","affiliation":[{"name":"1Comprehensive Sickle Cell Center, Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Gladwin","sequence":"additional","affiliation":[{"name":"4University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-2108","authenticated-orcid":false,"given":"Punam","family":"Malik","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Cincinnati Children\u2019s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-2175","authenticated-orcid":false,"given":"Charles T.","family":"Quinn","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Cincinnati Children\u2019s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8584-4194","authenticated-orcid":false,"given":"Santosh L.","family":"Saraf","sequence":"additional","affiliation":[{"name":"1Comprehensive Sickle Cell Center, Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"38","key":"2026080611221328700_bib1","doi-asserted-by":"crossref","first-page":"e35237","DOI":"10.1097\/MD.0000000000035237","article-title":"Understanding sickle cell disease: causes, symptoms, and treatment options","volume":"102","author":"Elendu","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"2026080611221328700_bib2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.24562","article-title":"Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia","volume":"91","author":"Quinn","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"2026080611221328700_bib3","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/bloodadvances.2023011397","article-title":"In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation","volume":"8","author":"Leonard","year":"2024","journal-title":"Blood Adv"},{"issue":"10","key":"2026080611221328700_bib4","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1681\/ASN.0000000804","article-title":"Management of kidney disease with sickle cell disease","volume":"36","author":"Abbasi","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"2026080611221328700_bib5","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/bloodadvances.2025017204","article-title":"KDIGO-defined kidney dysfunction predicts long-term outcomes in a multi-center cohort of adults with sickle cell disease","volume":"9","author":"Zhang","year":"2025","journal-title":"Blood Adv"},{"issue":"23","key":"2026080611221328700_bib6","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/bloodadvances.2019000916","article-title":"American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease","volume":"3","author":"Liem","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2026080611221328700_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41581-022-00540-9","article-title":"The nephropathy of sickle cell trait and sickle cell disease","volume":"18","author":"Ataga","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"2026080611221328700_bib8","first-page":"CD009191","article-title":"Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease","volume":"12","author":"Sasongko","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2026080611221328700_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bjh.15651","article-title":"Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease","volume":"184","author":"Thrower","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"2026080611221328700_bib10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/sj.ki.5002746","article-title":"The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes","volume":"73","author":"Mohanram","year":"2008","journal-title":"Kidney Int"},{"issue":"11","key":"2026080611221328700_bib11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/qjmed\/hcv049","article-title":"Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis","volume":"108","author":"Cheungpasitporn","year":"2015","journal-title":"QJM"},{"issue":"3","key":"2026080611221328700_bib12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2009.12.042","article-title":"The role of the renin-angiotensin system in the regulation of erythropoiesis","volume":"56","author":"Vlahakos","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2026080611221328700_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/bs.vh.2017.02.001","article-title":"Erythropoietin regulation by angiotensin II","volume":"105","author":"Kim","year":"2017","journal-title":"Vitam Horm"},{"issue":"4","key":"2026080611221328700_bib14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","article-title":"Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity","volume":"118","author":"Machado","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2026080611221328700_bib15","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1002\/ajh.24810","article-title":"Losartan for the nephropathy of sickle cell anemia: a phase-2, multicenter trial","volume":"92","author":"Quinn","year":"2017","journal-title":"Am J Hematol"},{"issue":"8","key":"2026080611221328700_bib16","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.bbamcr.2013.04.006","article-title":"Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative","volume":"1833","author":"Chamorro","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2026080611221328700_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1634\/stemcells.18-4-287","article-title":"Effect of angiotensin II on hematopoietic progenitor cell proliferation","volume":"18","author":"Rodgers","year":"2000","journal-title":"Stem Cells"},{"issue":"4","key":"2026080611221328700_bib18","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/trf.12904","article-title":"Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers","volume":"55","author":"Saraf","year":"2014","journal-title":"Transfusion"},{"issue":"2","key":"2026080611221328700_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.semnephrol.2003.11.006","article-title":"Angiotensin II receptor type 1 expression in erythroid progenitors: implications for the pathogenesis of postrenal transplant erythrocytosis","volume":"24","author":"Mrug","year":"2004","journal-title":"Semin Nephrol"},{"issue":"16","key":"2026080611221328700_bib20","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.2021011044","article-title":"Molecular and cellular mechanisms that regulate human erythropoiesis","volume":"139","author":"Caulier","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2026080611221328700_bib21","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.2022016741","article-title":"Epo-IGF1R cross talk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm","volume":"140","author":"Hsieh","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026080611221328700_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MOH.0000000000000328","article-title":"Characterization, regulation, and targeting of erythroid progenitors in normal and disordered human erythropoiesis","volume":"24","author":"Dulmovits","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"2026080611221328700_bib23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1242\/bio.201410686","article-title":"Localized SCF and IGF-1 secretion enhances erythropoiesis in the spleen of murine embryos","volume":"4","author":"Tan","year":"2015","journal-title":"Biol Open"},{"key":"2026080611221328700_bib24","first-page":"1563","article-title":"Immunology of IL-12: an update on functional activities and implications for disease","volume":"19","author":"Ullrich","year":"2020","journal-title":"EXCLI J"},{"issue":"1","key":"2026080611221328700_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/BS9.0000000000000002","article-title":"Interleukin-12 supports in vitro self-renewal of long-term hematopoietic stem cells","volume":"1","author":"Zhang","year":"2019","journal-title":"Blood Sci"},{"issue":"4","key":"2026080611221328700_bib26","doi-asserted-by":"crossref","first-page":"e0229959","DOI":"10.1371\/journal.pone.0229959","article-title":"Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: a systematic literature review and meta-analysis","volume":"15","author":"Ataga","year":"2020","journal-title":"PLoS One"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/783\/2536543\/blood_bld-2026-033813-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/783\/2536543\/blood_bld-2026-033813-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:22:29Z","timestamp":1786029749000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/6\/783\/568819\/Renin-angiotensin-aldosterone-system-inhibition"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033813","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,6]]},"published":{"date-parts":[[2026,8,6]]}}}